Leerink Partners analyst David Risinger has reiterated their bullish stance on CNTA stock, giving a Buy rating on September 9.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Risinger has given his Buy rating due to a combination of factors that highlight Centessa Pharmaceuticals’ promising prospects. Firstly, the company’s ORX750 drug is anticipated to outperform competitors in terms of efficacy, with expectations of superior results in ongoing trials. This optimism is bolstered by recent competitor data that suggests room for ORX750 to demonstrate its potential as a best-in-class orexin agonist.
Additionally, management’s confidence in the drug’s pharmacokinetic profile, which allows for flexible dosing options, adds to its appeal. The transient nature of visual disturbances associated with similar drugs has been downplayed by experts, further supporting the drug’s safety profile. Overall, these factors contribute to a positive outlook for Centessa Pharmaceuticals, justifying the Buy rating with a price target of $36.
CNTA’s price has also changed dramatically for the past six months – from $15.800 to $22.710, which is a 43.73% increase.